
Vutrisiran, a gene-silencing drug, led to impressive reductions in all-cause death and recurrent cardiovascular events in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), suggesting a new treatment option for this fatal disease.


coremsg

Results of the HELIOS-B trial indicate patients may soon have a second drug class available to slow the progression of transthyretin-mediated amyloidosis with cardiomyopathy, a fatal disease.

Impressive Results With Gene Silencer in ATTR-Cardiomyopathy

vutrisiran-a-gene-silencing-drug-demonstrates-significant-reductions-in-mortality-and-cardiovascular-events-in-patients-with-transthyretin-mediated-amyloidosis-cardiomyopathy


Vutrisiran, a Gene-Silencing Drug, Demonstrates Significant Reductions in Mortality and Cardiovascular Events in Patients with Transthyretin-Mediated Amyloidosis Cardiomyopathy
